Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 20;11:687564. doi: 10.3389/fonc.2021.687564

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 She, Su, Shen and Liu

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Brain scan of patient number 5 (IDH1−; in situ recurrence. The interval time between the end of CCRT and the treatment of anlotinib combined with TMZ was 3.8 months). (A1–A3) Perfusions maps at the time of suspected recurrence; (A4, A5) Perfusions maps at the time of diagnosis of recurrence 1.1months later, just watch and see, no additional therapy; (B1–B4) MR spectroscopy (MRS) at the time of suspected recurrence; (B5, B6) MR spectroscopy (MRS) at the time of diagnosis of recurrence 1.1 months later, just watch and see, no additional therapy; (C1–C5) Contrast-enhanced MRI; (D1–D5) MRI-Flair; MRI images followed-up every 1 to 3 months before and after treatment. The arrow refers to the area of recurrence. The patient achieved complete remission after treatment and had a progression-free survival time of 16.8 months.